* AgriBioTech Inc., of Henderson, Nev., entered an agreement with Mycogen Corp., of San Diego, under which the companies will develop insect-resistant alfalfa varieties. They have agreed to share equally the captured incremental value, under the terms of the exclusive license. Mycogen will screen its Bt gene and strain library to identify genes active against the insect pests targeted by AgriBioTech, and will provide selected genes in an expression cassette ready for transformation into alfalfa.

* Hybridon Inc., of Milford, Mass, signed a lease termination agreement for its former corporate facility in Cambridge, Mass., and Pfizer Inc., of New York, has signed a lease for the facility. Hybridon expects a one-time receipt of $6.5 million, and expects to save $3.6 million annually. The move is part of Hybridon's previously disclosed restructuring. (See BioWorld Today, July 22, 1998, p. 1.)

* Unigene Laboratories Inc., of Fairfield, N.J., received $3 million in milestone payments from Warner-Lambert Co., of Morris Plains, N.J., for achieving benchmarks in the development of an oral calcitonin product to treat osteoporosis. Under the terms of their July 1997 licensing agreement, Unigene has received a total of $11 million from Warner-Lambert, and is eligible for $43.5 million more. (See BioWorld Today, July 3, 1997, p. 1.)

No Comments